Cardiovascular drug research and development reaches a key milestone, and two major track catalysts determine the direction of the sector (Goldman Sachs)
Goldman Sachs Global Medical Research pointed out that after the failure of AZN/IONS's CARDIO-TTRansform trial, two core catalysts in the cardiovascular field attracted much attention in the third quarter: NVS/IONS's pelacarsen (HORIZON trial) and NVO's ziltiv
Goldman Sachs Global Medical Research pointed out that after the failure of AZN/IONS's CARDIO-TTRansform trial, two core catalysts in the cardiovascular field attracted much attention in the third quarter: NVS/IONS's pelacarsen (HORIZON trial) and NVO's ziltivekimab (ZEUS study). The results of these two trials will test whether the new pharmacological mechanism can be converted into clinical benefits and trigger significant fluctuations in the stock prices of related companies. Currently, investors have low expectations for the HORIZON trial, which means there is room for "surprise-than-expected" upside. One sentence conclusion: The cardiovascular field has entered a data-intensive period. The success or failure of the HORIZON trial will determine the fate of the Lp(a) track and will also bring huge trading opportunities to the entire sector. Good/bad: If successful, it will be good for Novartis (NVS), Ionis (IONS) and other players in the track such as Amgen (AMGN). If it fails, it will be negative for the entire Lp(a) drug development direction. The current market has some expectations for negative results, but success may be underpriced. Catalysts: 1) Data readout from the HORIZON trial of NVS/IONS in the third quarter of 2026; 2) Results from the ZEUS study of NVO; 3) Subsequent clinical data from other oral or long-acting Lp(a) drugs.